Authors: Tristan Free, Future Science Group
The first set of data from Pfizer (NY, USA) and BioNTech’s (Mainz, Germany) Phase III clinical trial for their COVID-19 vaccine candidate, BNT162b2, indicates a 90% efficacy rate.
“Today is a great day for science and humanity,” said Albert Bourla, Pfizer Chairman and CEO. “With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.”
